EGFR and non-small cell lung carcinoma: The impact of neoadjuvant EGFR-TKIs on survival remains inconclusive.<h4>Conclusions</h4>Neoadjuvant EGFR-TKIs showed objective responses in approximately half of EGFR-sensitive NSCLC patients with a tolerable adverse effect profile.